Purpose Our goal was to develop a nomogram by exploiting intratumour heterogeneity on CT and PET images from routine 18 F-FDG PET/CT acquisitions to identify patients with the poorest prognosis. Methods This retrospective study included 116 patients with NSCLC stage I, II or III and with staging 18 F-FDG PET/CT imaging. Primary tumour volumes were delineated using the FLAB algorithm and 3D Slicer™ on PET and CT images, respectively. PET and CT heterogeneities were quantified using texture analysis. The reproducibility of the CT features was assessed on a separate test-retest dataset. The stratification power of the PET/CT features was evaluated using the Kaplan-Meier method and the log-rank test. The best standard metric (functional volume) was combined with the least redundant and most prognostic PET/CT heterogeneity features to build the nomogram.
Introduction
Lung cancer is the first cause of cancer death in men and the second in women [1] . 18 F-FDG PET/CT imaging is used routinely for diagnosis and staging in non-small-cell lung cancer (NSCLC) [2] . Tumour activity accumulation is currently assessed on PET images using standardized uptake value (SUV) metrics such as maximum, peak and mean SUV. In the same context, the higher resolution CT images from PET/CT acquisitions are currently exploited only for attenuation correction and to localize PET tracer uptake. More recently, prognostic models based on different PET and CT imagederived features have been designed [2] . The value of intratumour heterogeneity in NSCLC has been assessed both on 18 F-FDG images [3] [4] [5] [6] [7] and on unenhanced/contrastenhanced CT images [8] [9] [10] [11] with promising results in terms of prediction of response, recurrence and survival, often with higher and/or complementary value compared with standard volume or intensity metrics.
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The term Bheterogeneity^conveys different meanings depending on the imaging modality. On 18 F-FDG PET, it refers to the spatial distribution of radiotracer uptake, which could at least partly reflect underlying processes such as metabolism, hypoxia and cellular proliferation [12] . On the other hand, on unenhanced CT, it refers to the variability in tissue densities that could result from spatially varying vascularization and/or necrosis [9] . Finally, on contrast-enhanced CT, heterogeneity refers to the spatial variability in microvessel density [8] . This heterogeneity of image voxel intensities can be quantified by different numerical methods including textural features (TF), intensity histogram analysis or filtering combined with statistical and frequency-based methods [13] .
In the vast majority of recent studies, characterization of intratumour heterogeneity has been considered separately on either CT or PET images, but rarely simultaneously on images from both modalities in the context of assessing their complementary prognostic value. In one such study, 18 F-FDG uptake heterogeneity was quantified using histogram-derived entropy only, combined with parameters extracted from both contrastenhanced perfusion CT images and the attenuation CT component of PET/CT [8] . In another study a model was built using a small dataset of 27 patients, combining PET and CT image-derived features for predicting postradiotherapy tumour progression [14] . In addition, previous studies investigating CT-derived features exploited dosimetry [9] or diagnostic CT images [15] rather than the CT component of PET/CT acquisitions.
In NSCLC, patients with stage I disease have a much better outcome than those with stage II or III disease. PET/CTderived features are unlikely to change the evaluation of patients with stage I disease, as these patients usually have small tumour volumes. There is therefore a limited amount of information that can be extracted from them. On the contrary, stage II and III tumours exhibit a much higher range of volumes and heterogeneity, and it is thus expected that these features could potentially improve prognosis stratification in these patients.
The purpose of this work was thus to investigate the potential added prognostic value compared with staging alone of tumour and heterogeneity features extracted from both PET and CT components of routinely acquired PET/CT scans in NSCLC patients by developing a multiparametric nomogram with better stratification among patients with stage II/III compared with stage I disease.
Materials and methods

Patient cohort and imaging
This retrospective study included 116 patients with NSCLC stage I, II or III diagnosed between 2008 and 2012 at the University Hospital of Poitiers, France. Treatment consisted of surgery and/or (chemo)radiotherapy. Of the 116 patients, 14 had palliative chemotherapy only. Radiotherapy was with curative intent in all patients (mean dose 59.4 Gy).
A maximum of 2 weeks after diagnosis, all patients underwent an 18 F-FDG PET/CT scan on a Philips GEMINI PET/CT scanner (Philips Medical Systems, USA) following a standard routine protocol: image acquisition was started after the patient had fasted for 6 h and 60 ± 5 min after injection of 5 MBq/kg of 1 8 F -F D G ( 4 2 4 ± 9 7 M B q , r a n g e 220 -690 MBq). CT images without contrast enhancement or respiratory gating (free-breathing images) were acquired (120 kV, 100mAs), with an in-plane resolution of 0.853 × 0.853 mm and a 5-mm slice thickness. PET data were acquired using 2 min per bed position and images were reconstructed using a 3D row-action maximum likelihood algorithm (RAMLA; two iterations, relaxation parameter 0.05, 5 mm full-width at half-maximum 3D gaussian postfiltering, 4 × 4 × 4 mm voxels). All PET images were corrected for attenuation using the acquired CT data.
Concerning clinical variables, in addition to clinical stage (in terms of T and N stage), treatment modality, age, gender, histology and smoker status were considered.
PET and CT image-derived parameters
Only primary tumours were analysed. Metabolically active tumour volumes (MATV) were automatically delineated in 3D on PET images with the fuzzy locally adaptive Bayesian (FLAB) algorithm. This procedure has been previously extensively validated for repeatability, accuracy and robustness in delineating both homogeneous and heterogeneous MATV [16] [17] [18] [19] [20] . A similarly validated and recommended approach exploiting the 3D Slicer™ software was used to semiautomatically delineate morphological tumour volumes in 3D on the CT images [21] . The tumours were subsequently characterized quantitatively by extracting several metrics from the delineated volumes: anatomical tumour volume (ATV) and associated intensity measurements from the CT images, and MATV and associated standard SUV metrics (SUV max , SUV mean ) from the PET images. In both PET and CT volumes, intratumour heterogeneity was quantified in 3D using TF analysis after quantization into 64 grey levels, as previously recommended [5, 11, 22, 23] . Quantization was performed using Eq. 1:
where I max and I min are the maximum and minimum Hounsfield units from the CT image and SUV from the PET image, respectively, and q = 64. Second-order TF (e.g. entropy, dissimilarity) were derived from a single co-occurrence matrix taking into consideration all 13 orientations simultaneously, as this procedure was previously shown to lead to parameters with higher complementary values with respect to volume [5] . For PET heterogeneity features, only TF demonstrated in previous studies to be robust [24] and reproducible [22] , and with potential complementary value to MATV [5] , were considered: namely local entropy and dissimilarity, high-intensity large-area emphasis (HILAE) and zone percentage (ZP). CT heterogeneity histogramderived metrics and TF were also calculated (Supplementary Table 1 ). As a first step, their reproducibility was assessed in the present work using a specific dataset of test-retest acquisitions in patients with NSCLC, from the Reference Image Database to Evaluate Therapy Response (RIDER) study available from The Cancer Imaging Archive (TCIA) [25] . We used this external test-retest database with unenhanced CT scans, given that our study was retrospective so it was not possible to have test-retest CT scans in the patients of the present cohort.
To the best of our knowledge, the RIDER dataset is the only publicly available CT test-retest dataset.
CT feature reproducibility was assessed with BlandAltman analysis by reporting the mean and standard deviation (SD) of the differences between the two measurements. Lower and upper reproducibility limits were also calculated as ±1.96 × SD. Before being considered for inclusion in the nomogram, CT features were first selected based on their reproducibility. Features demonstrating SD >10 %, corresponding to twice the variability of tumour volume measurements, were excluded from further analysis.
Nomogram construction
Statistical analyses were performed using MedCalc™ (MedCalc Software, Ostend, Belgium). Correlations between features were quantified using Spearman's rank coefficient (r s ). In order to reduce false-positive rates and inflation of type I errors due to multiple testing, we reduced the number of features that were divided into four categories: (1) clinical variables, (2) volume and standard metrics, (3) PET heterogeneity and (4) CT heterogeneity. Our goal was to build a nomogram combining the best features of each category in order to improve the stratification provided by stage alone (Fig. 1a) . Staging was considered a baseline from which to improve, since staging has previously been shown to provide significant stratification especially for stage I relative to stages II and III. Therefore in this study, PET/CT features were investigated in patients with stage II/III disease (N = 87) to identify better those with the poorest prognosis, i.e. cumulative factors indicating a poor prognosis. To this end, the selection of features to exploit was based on both their stratification power and their redundancy: a feature was considered for inclusion in the nomogram only if it had shown a prognostic value and had a correlation with other features <0.7 [26] .
The stratification power of the different parameters was assessed using the Kaplan-Meier method and log-rank test, with cut-off thresholds determined by receiver operating characteristics curve analysis according to Youden's index [27] . The parameters were ranked according to their discriminating power based on hazard ratio (HR) and associated p value. Correction for multiple testing was performed using the false discovery rate Benjamini-Hochberg step-up procedure, that involves declaring positive discoveries at level α (here α = 0.05), among the k = 1…K tested variables ordered according to their p values (p in increasing order), those ranked above the one satisfying the condition p(k) ≤ k K × α [28] . In order to evaluate the improvement in prognosis stratification amongst patients with stage II or III disease, by adding PET and/or CT heterogeneity features compared to clinical staging alone, the resulting Kaplan-Meier curves were compared using median overall survival (OS) in each group, HR and associated 95 % confidence intervals (CI). Higher values of HR, with 1 being excluded from the 95 % CI, indicated models with better stratification power.
Results
Survival and standard clinical staging
Mean follow-up was 26 months (range 1.5 -74 months). Mean and median OS were 36.7 (95 % CI 31.1 -42.2) and 22.3 months (95 % CI 15.6 -36.2), respectively (Fig. 1a) . At the last follow-up 71 patients were dead and 45 alive. Clinical stage was associated with survival significantly better in patients with stage I disease (median survival not reached as only 20.7 % of patients died) than in those with stage II (HR 4.7) and III disease (HR 6.6; p < 0.0001; Tables 1 and 2 ). Patients with stage III disease had worse survival than those with stage II disease (median OS of 21.2 vs. 14.5 months, HR 1.4; Fig. 1b ). Amongst patients with stage II and III disease, those with N0 disease (n = 15) had slightly better prognosis than those with N+ disease (n = 72), although the trend was not significant (p = 0.5), and N stage was highly correlated (r = 0.84) with clinical stage. Finally, patients with stage IIIA disease (n = 30) had slightly better survival than those with stage IIIB disease (n = 27), although the difference was not significant (p = 0.1).
CT feature reproducibility
In the test-retest dataset, the reproducibility of the ATV measurement was −1.7 ± 4.9 %, with lower and upper reproducibility limits of −11.2 % and +7.9 %. Histogram-derived entropy was the most reproducible feature with a mean difference of −1.2 ± 2.0 %. Seven heterogeneity features were sufficiently reproducible (SD <10 %; Supplementary Table 1) to be further considered.
Delineation and tumour volumes
All tumours in the 116 patients were delineated successfully. images had no prognostic value, whereas SUV max and SUV mean were not significant after correction for multiple testing. ATV and MATV were both prognostic factors, but were highly correlated (r s = 0.80; Table 2 , Fig. 2a) . MATV was selected for tumour volume quantification and was included in the nomogram with a cut-off value of 35 cm 3 as it provided higher stratification than ATV (HR 2.4 vs. 1.9; Table 2 ).
Amongst the PET heterogeneity features, co-occurrence entropy and HILAE had a correlation of <0.7 with both MATV and stage. The entropy was selected to quantify PET heterogeneity in the nomogram (cut-off value 7.3), with an associated HR of 1.9 (p = 0.01) since HILAE was not significant (p = 0.2). Amongst the seven reproducible CT heterogeneity features, all exhibited a correlation of <0.7 with MATV, clinical stage or PET entropy and five had a statistically significant prognostic value ( Table 2) . CT ZP (cut-off value 0.8) was selected since it had the best stratification power (HR 2.1, p = 0.003).
The nomogram combining stage and MATV constituted our Bstandard^nomogram (i.e. without any consideration of CT or PET heterogeneity). It resulted in a median OS of 21.8 and 7.5 months for lower and higher risk groups, respectively, with HR of 4.3 and 11.1 compared to patients with stage I disease ( Table 3 , Supplementary Fig. 2a ), and HR of 2.6 between lower and higher risk groups. Adding heterogeneity parameters into the model led to increased stratification, with OS of 21.8 vs. 8.5 months (HR 2.9) and 21.2 vs. 6.5 months (HR 2.7) for PET entropy and CT ZP, respectively (Table 3 , Supplementary Fig. 2b, c) . HRs with respect to patients with stage I disease similarly increased for PET entropy and CT ZP to 4.5 and 4.8, respectively, for the lower risk group, and to 13.1 and 12.8 for the higher risk group. The best stratification was obtained by including all four parameters in the model (Table 3 , Fig. 1c ) with a median OS of 21.2 months in the lower risk group vs. 6.5 months for the higher risk group, resulting in a HR of 3.6 between the two groups. HRs compared to patients with stage I disease increased to 4.9 and 17.4.
As features were added, the number of patients in the higher risk group decreased from 57 using stage alone to 15 using the proposed nomogram. The percentage of events in the higher risk group increased to 100 % (vs. 77 % with clinical stage only), whereas the median OS decreased from 14.5 to 6.5 months. The proposed nomogram therefore led to a more useful stratification, patients with stage II/III disease being well stratified (HR 3.6) between a larger intermediate risk group (N = 72) and a smaller higher risk group (N = 15) with very short OS (95 % CI 3.9 to 9.9 months) and an 18-month survival of 0 %.
Discussion
Quantification of tumour heterogeneity from either CT or PET/CT images has been extensively considered for predicting outcome in patients with NSCLC. However, most previous studies focused on either CT or PET image-derived features, and rarely on both modalities simultaneously to investigate their complementary value. In addition, recent studies investigating the use of CT for characterization of intratumour heterogeneity have used dosimetry or diagnostic CT scans, rather than the CT component of PET/CT scans [9, 15] . The present study investigated the combination of CT and PET heterogeneity features using the images from both modalities acquired on a PET/CT scanner. Several TFs calculated within tumour volumes derived from anatomical (CT) and functional (PET) images were reproducible and associated with OS. Firstly, our results confirm the established prognostic value of clinical staging and primary tumour volume. Secondly, their addition to higher order PET and CT heterogeneity metrics led to a nomogram with higher stratification power. With respect to characterization of tumour heterogeneity from non-enhanced CT images, we evaluated the reproducibility of features using test-retest non-enhanced CT acquisitions of lung tumours. Bland-Altman analysis showed that the semiautomatic morphological tumour volume delineation step on CT images had high test-retest reproducibility (−1.7 ± 4.9 %), much lower than the ±15 % previously shown for PET [20, 29] . The reproducibility of histogram-derived TFs and TFs computed on the same test-retest CT images has already been evaluated with concordance correlation coefficients (CCC) [11, 23] , concluding that all histogram-derived parameters were reproducible, in contrast to our findings identifying only SD, uniformity and entropy as reproducible. This might be explained by the fact that the Bland-Altman method could be more conservative than CCC. The majority of the investigated features (27 out of 34) in this work exhibited insufficient reproducibility.
Most CT-derived TFs were correlated with ATV, and some were also moderately correlated with MATV. We emphasize that our goal was to add features with complementary value to parameters that already have established prognostic value (e.g. stage and volume). Therefore, adding to the nomogram PET and CT features that correlated with volume or stage would not improve stratification. The chosen PET and CT features also had to be nonredundant: tissue density heterogeneity on CT (ZP) was not correlated with 18 F-FDG uptake heterogeneity on PET (entropy) with r s = −0.11 ( Supplementary Fig. 3 ).
Patients exhibiting higher intratumour 18 F-FDG uptake heterogeneity had poorer outcomes irrespective of treatment modality, corroborating recent results [4, 6, 7, 14] . 18 F-FDG accumulation is assumed to be mediated by multiple physiological processes including metabolism, vascularization, perfusion, aggressiveness and hypoxia [30, 31] , which may be responsible for tumour heterogeneity. It has recently been shown that PET tumour heterogeneity may be associated with tumour vascularization [32] . It is also known that most hypoxic cells are more resistant [33] .
Tissue density heterogeneity on CT within the primary tumour was also found to be associated with survival, lower heterogeneity (in contrast to higher 18 F-FDG heterogeneity) being associated with poorer outcome (Fig. 3) . Tumour heterogeneity on CT is due to the presence of different types of cells (fibroblasts, collapsed cells, mucin, carcinoma cells, etc.) and tumour growth is accompanied by destruction of collagen fibrosis, which suggests that the air-containing region decreases and the solid region increases [34] . On the one hand, our findings contradict those of other studies that have shown an association between higher tissue heterogeneity and poorer prognosis [9, 15, 35] on dosimetry or diagnostic CT with different image characteristics. On the other hand, our results are in agreement with those of another recent study showing that lower heterogeneity measured on the attenuation CT component of PET/CT was associated with poorer survival [8] . This result was obtained using entropy calculated in the intensity histogram, which was also included in our study and showed certain prognostic power, lower values being associated with worse survival. Although we chose ZP for the nomogram instead, given that it had higher stratification power, the overall results of the two studies are indeed comparable. However, given the limited evidence currently available associating higher homogeneity on attenuation CT with poorer prognosis in NSCLC, further studies are needed to draw definitive conclusions.
Compared with our previous studies [4, 5] , 15 additional patients were included and OS was updated with follow-up until September 2014, and the entire statistical analysis was redone. It was shown in the present cohort that combining an increasing number of features improved the stratification of patients, resulting in a nomogram combining clinical stage, tumour functional volume, PET heterogeneity (local entropy) and CT heterogeneity (ZP), thus suggesting that complementary prognostic value can be extracted not only from the 18 FDG PET scan, but also using the attenuation CT scan from routine PET/CT. This should be emphasized, as previous studies have focused on contrast-enhanced, diagnostic or dosimetry CT, not the CT component of PET/CT. Our results contribute to the accumulating evidence that quantification of tumour heterogeneity on both PET and CT can help identify NSCLC patients with the poorest outcome. Our nomogram identified patients with a very poor prognosis, who could be offered alternative strategies (targeted therapies or treatment intensification) at diagnosis using baseline PET/CT images that are acquired as the standard for staging in routine clinical management of NSCLC. The present nomogram was Btrainedâ nd fitted to the present patient cohort and will thus require validation in prospectively recruited patients.
F-
One limitation was the variability in treatment modalities, although patients with metastatic disease were not considered. Yet the results indicate that heterogeneity on PET and CT may predict survival independent of treatment modality: the nomogram obtained by excluding patients treated with palliative chemotherapy only showed similar stratification ( Supplementary Fig. 4) . A second limitation concerns the evaluation of the reproducibility of the CT features and comparison with the prognostic value extracted from perfusion or contrast-enhanced CT scans. We could not perform the reproducibility evaluation in our cohort, nor could we compare the prognostic value with that of other CT imaging modalities, since in the present cohort, only routine PET/CT acquisitions were available. Regarding reproducibility, we used a publicly available dataset that has been previously used [11, 23, 25] .
Another limitation was that we did not characterize lymph nodes, only the primary tumour. Note there was no significant difference (p > 0.2) between the distributions of the PET and CT heterogeneity features of the primary tumour according to N stage ( Supplementary Fig. 5 ). Because staging incorporates lymph node status, the information is contained in the nomogram. It would be interesting to include the PET/CT image features of lymph nodes in future work, although lymph node volumes are often smaller than those of primary tumours, which would limit the amount of exploitable texture information [5] . Another improvement could be the use of PET/CT images with more appropriate properties for textural feature analysis resulting from improved reconstruction schemes (smaller voxels, higher resolution) [36] and respiratory-gated acquisitions [37] . The last limitation concerns the combination of features and the statistical evaluation of the increased stratification. We considered a simple addition of risk factors to design the proposed nomogram, dichotomizing patients with stage II and III disease into a more specific higher risk group (patients having all four risk factors: stage III, large functional volume, high 18 F-FDG PET heterogeneity and low CT heterogeneity) and a larger, lower risk group (patients having some but not all risk factors). The use of methods from the field of machine learning [38] may allow the building of more robust nomograms, and could allow statistical comparison of the performance of the models, although this would require larger groups of patients. This will be the focus of future investigations, along with validation of the proposed nomogram in a prospective cohort, which is currently being recruited.
Conclusion
Tumour heterogeneity quantified with textural features on the CT and PET components of routine 18 F-FDG PET/CT images without contrast enhancement can provide complementary prognostic value in NSCLC. A four-variable nomogram was designed and showed higher stratification power than standard clinical staging. Amongst patients with stage II and III disease, those with stage III disease, larger functional tumour volume, higher 18 F-FDG PET heterogeneity, and lower tissue density heterogeneity on CT had a very poor outcome, with an 18-month survival of 0 % and a median OS of only 6.5 months. These results need to be validated in a prospective study. 
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